Golden, CO – According to filings with the U.S. Securities and Exchange Commission, Theralink Technologies is raising $4,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Mick Ruxin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Theralink Technologies

At Theralink Technologies, our approach is based on more than 16 years of research and development. Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions. Our phosphoproteomic RPPA approach is the only platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue. Our advanced technology exploits our understanding of the drug-receptor and drug-protein interactions that drive treatment responses. The Theralink assay has been developed to provide physicians with a treatment decision support tool to assist in selecting therapies that are more likely to result in responses to treatment.

To learn more about Theralink Technologies, visit http://theralink.com/

Contact:
Mick Ruxin, President and Chief Executive Officer
888-585-4923
https://www.linkedin.com/in/mick-ruxin-m-d-ab1595/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved